Galapagos NV (GLPG)
27.19
-0.08
(-0.29%)
USD |
NASDAQ |
May 28, 16:00
26.01
-1.18
(-4.34%)
After-Hours: 20:00
Galapagos Revenue (Quarterly): 67.81M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 67.81M |
| December 31, 2023 | -225.21M |
| September 30, 2023 | 130.68M |
| June 30, 2023 | 294.69M |
| March 31, 2023 | 62.91M |
| December 31, 2022 | -172.72M |
| September 30, 2022 | 137.21M |
| June 30, 2022 | 146.58M |
| March 31, 2022 | 153.00M |
| December 31, 2021 | -95.47M |
| September 30, 2021 | 75.69M |
| June 30, 2021 | 168.45M |
| March 31, 2021 | 137.24M |
| December 31, 2020 | 186.15M |
| September 30, 2020 | 149.12M |
| June 30, 2020 | 109.68M |
| March 31, 2020 | 104.64M |
| December 31, 2019 | 120.90M |
| September 30, 2019 | 704.88M |
| June 30, 2019 | 65.99M |
| Date | Value |
|---|---|
| March 31, 2019 | 37.54M |
| December 31, 2018 | 109.77M |
| September 30, 2018 | 110.32M |
| June 30, 2018 | 59.31M |
| March 31, 2018 | 46.57M |
| December 31, 2017 | 46.18M |
| September 30, 2017 | 31.68M |
| June 30, 2017 | 29.63M |
| March 31, 2017 | 36.21M |
| December 31, 2016 | 85.78M |
| September 30, 2016 | 12.52M |
| June 30, 2016 | 32.40M |
| March 31, 2016 | 11.16M |
| December 31, 2015 | 7.868M |
| September 30, 2015 | 6.340M |
| June 30, 2015 | 13.12M |
| March 31, 2015 | 16.70M |
| December 31, 2014 | 25.29M |
| September 30, 2014 | 18.11M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-225.21M
Minimum
Dec 2023
704.88M
Maximum
Sep 2019
116.11M
Average
125.79M
Median
Revenue (Quarterly) Benchmarks
| UCB SA | -- |
| Mithra Pharmaceuticals SA | -- |
| Nyxoah SA | 1.326M |
| Celyad Oncology SA | -- |
| MDxHealth SA | 19.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 98.00M |
| Total Expenses (Quarterly) | 103.80M |
| EPS Diluted (Quarterly) | 1.488 |
| Enterprise Value | -2.050B |
| Gross Profit Margin (Quarterly) | 95.92% |
| Earnings Yield | 16.82% |
| Normalized Earnings Yield | -0.1404 |